Matthew McIntyre

Dr. Matthew McIntyre

orcid

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2026 in Stroke
Verified
Journal Article
Closed access
HCHuanwen Chen
Huanwen Chen
MMMatthew McIntyre
Matthew McIntyre
JKJay Kakadiya
Jay Kakadiya
PRPranjal Rai
Pranjal Rai
MEMuhammed Amir Essibayi
Muhammed Amir Essibayi
DLDhairya A Lakhani
Dhairya A Lakhani
BACKGROUND: Unruptured intracranial aneurysms (UIAs) affect up to 5% of the population, and rupture can lead to devastating subarachnoid hemorrhage. GLP-1RAs (glucagon-like peptide-1 receptor agonists) have anti-inflammatory and vasculoprotective effects, but their impact on aneurysm stability and subarachnoid hemorrhage outcomes is unexplored. This study evaluated whether GLP-1RA use is associated with reduced rupture risk and attenuated severity in the event of a rupture. METHODS: We conducted a retrospective cohort study using the TriNetX US Collaborative Network (2016–2024). Cohort 1 included patients with newly diagnosed, untreated UIA; cohort 2 included those who suffered aneurysm rupture. GLP-1RA exposure was defined as use before or within 3 months of UIA diagnosis (cohort 1) or before rupture (cohort 2). The primary outcome was aneurysm rupture risk in cohort 1. Secondary outcomes include presentation severity, vasospasm, and mortality in cohort 2. Propensity score matching balanced demographics, comorbidities, and medications. RESULTS: After propensity score match, cohort 1 of patients with untreated UIA included 8088 GLP-1RA users and 8088 nonusers. GLP-1RA use was associated with significantly lower probabilities of aneurysm rupture at 1-year (0.65% versus 1.51%; P <0.001), 3-year (1.18% versus 1.85%; P <0.001), and 5-year (1.49% versus 2.10%; P <0.001) timepoints, representing a 48% decrease in hazards (hazard ratio, 0.52 [95% CI, 0.38–0.69]). Among patients who suffered aneurysm rupture (cohort 2, N=298 after propensity score match), prerupture GLP-1RA use (n=149) was associated with lower rates of intraparenchymal hemorrhage (17.4% versus 33.6%; P <0.001), intraventricular hemorrhage (10.1% versus 23.5%; P <0.001), and clinically significant vasospasm (10.7% versus 24.2%; P =0.002), as well as numerically lower rates of 30-day mortality (9.4% versus 14.1%; P =0.21). CONCLUSIONS: For patients with untreated UIA, GLP-1RA use was associated with a 48% reduction in aneurysm rupture risk and, among those who suffered aneurysm rupture, milder clinical and radiographic severity. These findings suggest possible neuroprotective and vascular stabilizing effects of GLP-1RAs for patients with UIA.

23 May 2025 in Diagnostics
Verified
Journal Article
Open access
PDF file
HCHuanwen Chen
Huanwen Chen
MMMatthew McIntyre
Matthew McIntyre
MKMihir Khunte
Mihir Khunte
AMAjay Malhotra
Ajay Malhotra
MLMohamed Labib
Mohamed Labib
DGDheeraj Gandhi
Dheeraj Gandhi
Background: Neurosurgical interventions are often indicated for patients with subcortical, supratentorial intracerebral hemorrhage (ICH); however, the optimal treatment modality is controversial. Whether minimally invasive surgery (MIS) may be superior to conventional craniotomy (CC) or decompressive craniectomy (DC) in real-world clinical practice is unknown. Methods: This was a retrospective cohort study of hospitalization data from the 2016–22 Nationwide Readmissions Database. International Classification of Diseases—10th edition (ICD-10) codes were used to identify patients with primary supratentorial subcortical ICH who underwent neurosurgical treatment. Patients with ICH in other brain compartments (other than intraventricular hemorrhage) were excluded. Coprimary outcomes were routine discharge to home without rehabilitation needs (excellent outcome) and in-hospital mortality. Outcomes were compared between MIS versus CC and MIS versus DC, with multivariable adjustments for patient demographics and comorbidities. Results: A total of 3829 patients were identified; 418 underwent MIS (10.9%), 2167 (56.6%) underwent CC, and 1244 (32.5%) underwent DC. Compared to CC patients, MIS patients were less likely female (p = 0.004) but otherwise had similar patient characteristics; compared to DC patients, MIS patients were older, less likely female, more likely to have mental status abnormalities, more likely to have underlying dementia, less likely to undergo external ventricular drainage, more likely to have vascular risk factors (hypertension, hyperlipidemia, diabetes), and less likely to have underlying coagulopathy (all p < 0.05). After multivariable adjustments, MIS patients had higher odds of excellent outcomes compared to CC (OR 1.99 [95%CI 1.06–3.30], p = 0.039), and similar odds compared to DC (OR 1.10 [95%CI 0.66–1.86], p = 0.73). In terms of in-hospital mortality, MIS had lower odds compared to DC (OR 0.63 [95%CI 0.41–0.96], p = 0.032) and similar odds compared to CC (OR 0.81 [95%CI 0.56–1.18], p = 0.26). Conclusions: For patients with subcortical, supratentorial ICH requiring surgical evacuation, MIS was associated with higherhigher rates of excellent outcomes compared to CC and lower rates of in-hospital mortality compared to DC. However, since key variables such as hematoma size and symptom severity were not available, residual confounding could not be excluded, and results should be interpreted cautiously. Dedicated prospective or randomized studies are needed to confirm these findings.

1 January 2026 in Journal of Clinical Neurology
Verified
Journal Article
Open access
PDF file
JKJay Kakadiya
Jay Kakadiya
PRPranjal Rai
Pranjal Rai
GBGirish Bathla
Girish Bathla
VDVidhi Hiteshbhai Dhaduk
Vidhi Hiteshbhai Dhaduk
HCHuanwen Chen
Huanwen Chen
DLDhairya A Lakhani
Dhairya A Lakhani
Kakadiya J, et al. J Clin Neurol. 2026 ;22:e56. https://doi.org/10.3988/jcn.2026.0073

11 September 2025 in Pediatric Neurology
Verified
Journal Article
Closed access
AFAdeline L. Fecker
Adeline L. Fecker
MMMatthew McIntyre
Matthew McIntyre
JBJulia E. Babcock
Julia E. Babcock
Jenny L WilsonJenny L Wilson
Jenny L Wilson
GNGary Nesbit
Gary Nesbit
KCKelly Louise Collins
Kelly Louise Collins

1 December 2025 in Stroke
Verified
Journal Article
Closed access
HCHuanwen Chen
Huanwen Chen
MCMarco Colasurdo
Marco Colasurdo
JFJulie Falardeau
Julie Falardeau
MMMatthew McIntyre
Matthew McIntyre
AMAjay Malhotra
Ajay Malhotra
DGDheeraj Gandhi
Dheeraj Gandhi
BACKGROUND: Retinal artery occlusion (RAO) is a form of ischemic stroke per the American Heart Association, yet high-level evidence guiding management and prognostication is limited. The risk of future cerebral infarction following nonarteritic isolated RAO (iRAO; without concomitant cerebral infarction) is unclear. This study compares the risk of stroke recurrence following iRAO versus nondisabling ischemic cerebrovascular events (NICEs), including transient ischemic attacks and minor ischemic strokes. METHODS: This was a retrospective cohort study using the 2016 to 2022 Nationwide Readmissions Database in the United States. Adults hospitalized primarily for RAO or NICE were included. Patients who were functionally dependent at discharge or had moderate to severe stroke (National Institutes of Health Stroke Scale score >4), arteritis or vasculitis, or RAO and concomitant cerebral infarction were excluded from the primary analysis. Two-to-one propensity score matching was performed to balance baseline characteristics between cohorts. The primary outcome was subsequent cerebral infarction within 300 days. Cox regression models and multivariable adjustments were used to estimate hazard ratios. RESULTS: A total of 1 673 145 patients hospitalized for nondisabling stroke, transient ischemic attack, or RAO were identified; 17 388 (1.0%) had RAO, of whom 4507 (25.9%) had concomitant cerebral infarction and were excluded for primary analyses. After applying additional exclusion criteria and propensity score matching, 11 185 patients with nonarteritic iRAO and 22 757 patients with NICE remained. Patients with iRAO had a significantly lower risk of subsequent cerebral infarction (hazard ratio, 0.26 [95% CI, 0.20–0.35]; P <0.001). Absolute cerebral infarction rates at 30, 90, and 180 days were lower in patients with iRAO versus patients with NICE (0.5% versus 2.3%, 0.8% versus 3.1%, and 1.2% versus 4.3%, respectively; all P <0.001 for all). CONCLUSIONS: Nonarteritic iRAO events were associated with significantly lower risks of subsequent cerebral infarction compared with NICE. These findings suggest that iRAO events are not equivalent to ischemic cerebrovascular events in terms of risk of subsequent stroke. Further studies are needed to optimize secondary stroke prevention strategies tailored to nonarteritic iRAOs.

21 May 2026 in Neurology International
Verified
Journal Article
Open access
PDF file
PRPranjal Rai
Pranjal Rai
DMDaniel Mandel
Daniel Mandel
GBGirish Bathla
Girish Bathla
VDVidhi Hiteshbhai Dhaduk
Vidhi Hiteshbhai Dhaduk
RRRadhika Rajeev
Radhika Rajeev
DLDhairya A Lakhani
Dhairya A Lakhani
Background: Asymptomatic intracranial atherosclerotic arterial stenosis (ICAS) is an underrecognized entity for which vascular risk-factor optimization is the primary management strategy, with no current indication for routine antiplatelet therapy or endovascular intervention for primary stroke prevention. Glucagon-like peptide-1 receptor agonists (GLP-1RAs) reduce major adverse cardiovascular events, including stroke, in high-risk cardiometabolic populations, but their association with outcomes in asymptomatic ICAS is yet to be evaluated. The present study aims to evaluate the association between GLP-1RA use and cerebrovascular outcomes in adults with asymptomatic ICAS. Materials and Methods: We used the TriNetX US Collaborative Network (71 healthcare organizations) to identify adults (≥18 years) with ICAS between 1 January 2016 and 31 December 2025, and excluded patients with prior cerebral infarction, intracranial hemorrhage, or cerebrovascular ischemic syndromes. Exposure was defined as initiation of any GLP-1 receptor agonist (lixisenatide, semaglutide, liraglutide, tirzepatide, dulaglutide) during the 6 months before or on the date of index ICAS diagnosis. Outcomes were assessed at 1 year, and included ischemic stroke, all-cause mortality, and a composite of ischemic stroke or mortality. Propensity-score matching (1:1) was performed, including demographics, vascular risk factors, comorbidities, antithrombotics, lipid/diabetes therapies, and cardiometabolic laboratory/physiologic measures. Results: Before matching, 1746 GLP-1RA users and 71,792 non-users met inclusion criteria; after matching, 1728 patients remained in each cohort. GLP-1RA use was associated with lower 1-year risk of ischemic stroke (4.40% vs. 6.10%; hazard ratio [HR] 0.70, 95% CI 0.52–0.95; p = 0.044), lower all-cause mortality (3.40% vs. 9.40%; HR 0.35, 95% CI 0.26–0.47; p < 0.001), and lower composite outcome risk (7.50% vs. 15.00%; HR 0.48, 95% CI 0.39–0.59; p < 0.001). Notably, these associations were observed despite matching for HbA1c, LDL cholesterol, BMI, and systolic blood pressure, suggesting potential effects beyond measured cardiometabolic risk profiles. Conclusions: In this large, propensity-matched cohort of adults with a-ICAS, GLP-1RA use was associated with lower ischemic stroke, all-cause mortality, and composite outcome at 1 year. These findings are hypothesis-generating and require further prospective studies to confirm this observation.